Avapritinib Earns FDA Approval For Advanced Systemic Mastocytosis, Including Mast Cell Leukemia
Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.
Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.
Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.
Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.
James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.
To access the requested content, please tell us a bit more about yourself. * By submitting my information, I signify my acceptance of the…
With Martina Murphy, MD, the Oncology Brothers discuss the current landscape and standard of care regarding ovarian cancer treatment.
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.
Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.
Will handle most clerical duties associated with a medical clinic. The job of Patient Services Specialist (PSS) is divided into “stations.” Each station has a…